Skip to main content
  • Notice of Privacy Incident
  • Medicaid Provider Termination Alert: Revalidation deadlines are approaching. Failure by providers to revalidate will lead to termination and payment suspension. Check your account now at https://impact.illinois.gov/ to learn if your required revalidation is due this month. More revalidation information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 4, 2009

Drug Name Review Type Class Manufacturer
Sancuso New Drug Initial Review Antiemetic ProStrakan
Moxatag New Drug Initial Review Antibiotic MiddleBrook
Astepro New Drug Initial Review Nasal Preprarations Meda
Trilipix New Drug Initial Review Lipotropics � Other Abbott
Stavzor New Drug Initial Review Anticonvulsant Noven
Janumet New Drug Initial Review Diabetes Merck
Banzel New Drug Initial Review Anticonvulsant Eisai
Tekturna HCT New Drug Initial Review Direct Renin Inhibitor Novartis
Letairis New Drug Appeal Pulmonary Arterial Hypertension Gilead
Megace ES New Drug Appeal Progestin Par
Bystolic New Drug Appeal Beta-Blocker Forest
Pristiq New Drug Appeal SNRI Antidepressant Wyeth
Keppra XR New Drug Appeal Anticonvulsant UCB
Exforge New Drug Appeal Antihypertensive Combination Novartis
Tekturna New Drug Appeal Direct Renin Inhibitor Novartis